Compare AbbVie Inc (ABBV) vs iShares Core High Dividend ETF (HDV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs iShares Core High Dividend ETF — how do they compare? AbbVie Inc trades at $253.66 (market cap $449.91B), while iShares Core High Dividend ETF trades at $27.9. The key difference: AbbVie Inc pays a 2.72% dividend while iShares Core High Dividend ETF pays none. Which is the better fit depends on your goals.
| ABBV | HDV | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $28.09 |
52-Week Low | $184.85 | $23.63 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
HDV trades at $27.70, down 1.21% on the day, with a bullish technical signal driven by moving averages and neutral oscillators. The ETF focuses on high-quality, high-dividend U.S. stocks, currently yielding around 3.0%, and has outperformed the S&P 500 over five years with lower volatility. Recent news highlights its defensive sector tilt toward healthcare and energy, though this introduces oil price sensitivity.
The outlook for HDV is favorable for income-focused investors seeking stable dividends and lower market correlation, but risks include sector concentration in energy and competitive pressure from lower-cost dividend ETFs. Long-term performance hinges on sustained dividend growth from its quality-focused portfolio amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →
